Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
DATE PUBLISHED: 2022 Nov 26
JOURNAL:Respir Med
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/36462399?dopt=Abstract
Volume:206
Dupilumab as add-on treatment for severe uncontrolled asthma (SA) has shown to be effective and safe by phase-III-trials. Real-world data on clinical efficacy and safety is limited.
